Search results
Results from the WOW.Com Content Network
In the simple mono-compartmental case the volume of distribution is defined as: = /, where the in practice is an extrapolated concentration at time = 0 from the first early plasma concentrations after an IV-bolus administration (generally taken around 5 min - 30 min after giving the drug).
In practice, the drug concentration is measured at certain discrete points in time and the trapezoidal rule is used to estimate AUC. In pharmacology, the area under the plot of plasma concentration of a drug versus time after dosage (called “area under the curve” or AUC) gives insight into the extent of exposure to a drug and its clearance ...
Clark's rule is a medical term referring to a mathematical formula used to calculate the proper dosage of medicine for children aged 2–17 based on the weight of the patient and the appropriate adult dose. [1] The formula was named after Cecil Belfield Clarke (1894–1970), a Barbadian physician who practiced throughout the UK, the West Indies ...
To ensure that the drug taker who has poor absorption is dosed appropriately, the bottom value of the deviation range is employed to represent real bioavailability and to calculate the drug dose needed for the drug taker to achieve systemic concentrations similar to the intravenous formulation. [4]
One computational method which can be used to calculate IV estimates is two-stage least squares (2SLS or TSLS). In the first stage, each explanatory variable that is an endogenous covariate in the equation of interest is regressed on all of the exogenous variables in the model, including both exogenous covariates in the equation of interest and ...
At a practical level, a drug's bioavailability can be defined as the proportion of the drug that reaches the systemic circulation. From this perspective the intravenous administration of a drug provides the greatest possible bioavailability, and this method is considered to yield a bioavailability of 1 (or 100%). Bioavailability of other ...
A low drug load may cause homogeneity problems. A high drug load may pose flow problems or require large capsules if the compound has a low bulk density. By the time phase III clinical trials are reached, the formulation of the drug should have been developed to be close to the preparation that will ultimately be used in the market. A knowledge ...
And since is fraction of the drug that is removed per unit time measured at any particular instant, then if we divide the rate of elimination by the amount of drug in the body at time t, we get; K = d E t d t ÷ A t = ln 2 t 1 / 2 ≈ 0.693 t 1 / 2 {\displaystyle K={dE_{t} \over dt}\div A_{t}={\frac {\ln 2}{t_{1/2}}}\approx {\frac {0.693}{t ...